Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) reported 2025 results and a business update on Mar 26, 2026, highlighting clinical progress for sabirnetug and advancement of an Enhanced Brain Delivery (EBD) program.
Key items: $35.75M private placement for EBD candidates, $116.9M cash as of Dec 31, 2025 (runway into early 2027), topline ALTITUDE-AD Phase 2 results expected late 2026, and an IND target for an EBD lead candidate in mid-2027. R&D spend rose to $104.9M; net loss was $121.3M for 2025.
Positive
- $35.75M private placement to advance AβO-selective EBD portfolio
- Topline results for ALTITUDE-AD expected late 2026
- Lead EBD IND filing targeted for mid-2027
- Preclinical EBD candidates showed up to 40-fold brain exposure in non-human primates
- Cash balance of $116.9M as of Dec 31, 2025
Negative
- Cash runway expected only into early 2027
- Net loss increased to $121.3M in 2025
- Loss from operations rose to $123.8M in 2025
- R&D expense increased to $104.9M in 2025
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows two biotech peers (e.g., IMUX, OVID) moving up, but sector_momentum is flagged as not a coordinated move and ABOS’s own intraday direction is not specified. This points to today’s earnings news as a stock-specific catalyst rather than a broad sector driver.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Neutral | -1.0% | Reiterated cash runway into 2027 and ongoing Phase 2, but shares fell modestly. |
| Aug 12 | Q2 2025 earnings | Negative | -11.3% | Higher R&D and wider net loss, despite strong cash, saw shares drop sharply. |
| May 13 | Q1 2025 earnings | Neutral | +0.0% | Fully enrolled Phase 2, solid cash runway and higher R&D with flat price reaction. |
| Mar 27 | FY 2024 results | Neutral | +6.0% | Higher 2024 R&D and loss but strong cash supported a positive price reaction. |
| Nov 12 | Q3 2024 earnings | Negative | -16.9% | Rising R&D and net loss overshadowed cash strength, driving a steep share decline. |
Earnings releases have often coincided with mildly negative average moves, especially when expenses and losses expand despite solid cash.
Across the last five earnings updates from Nov 2024 through Nov 2025, Acumen consistently highlighted progress in its Phase 2 ALTITUDE‑AD trial and, later, the Enhanced Brain Delivery program. Cash balances stepped down from $258.9M in Q3 2024 to $136.1M by Q3 2025, while R&D spending and net losses widened. Markets reacted negatively to several of these reports, even when cash runway was reiterated into 2027, underscoring sensitivity to burn and loss trajectory.
Historical Comparison
Past earnings and annual results for ABOS have produced an average move of -4.64%, often skewing negative when burn and losses expand despite a reiterated cash runway.
Earnings updates show a steady progression of the Phase 2 ALTITUDE‑AD program toward late‑2026 topline data, alongside growing investment in Enhanced Brain Delivery while cash runway guidance has remained anchored around early 2027.
Market Pulse Summary
This announcement highlights full-year 2025 results, with $116.9M in cash and securities expected to fund operations into early 2027, alongside a growing R&D commitment of $104.9M. The key clinical focus remains Phase 2 ALTITUDE‑AD, with topline data anticipated in late 2026, and an EBD program IND targeted for mid‑2027. Investors may track cash usage, net loss trends, and progress toward these milestones when assessing future updates.
Key Terms
phase 2 medical
investigational new drug (ind) regulatory
open-label extension (ole) medical
subcutaneous administration medical
non-human primate medical
blood-brain barrier medical
AI-generated analysis. Not financial advice.
- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
- Lead clinical candidate IND filing in Acumen’s Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and
$35.75 million private placement to advance candidates in AβO-selective EBD portfolio - Cash, cash equivalents and marketable securities of
$116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 - Company to host conference call and webcast today at 8:00 a.m. ET
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.
“2025 was defined by significant clinical progress supporting our Phase 2 ALTITUDE-AD study investigating our lead therapeutic candidate, sabirnetug, and the expansion of our pipeline via a notable Enhanced Brain Delivery (EBDTM) partnership to develop a transferrin-receptor-targeting blood-brain barrier-penetrating therapy,” said Daniel O’Connell, Chief Executive Officer of Acumen. “2026 is poised to be transformative for Acumen. Topline results for ALTITUDE-AD are expected late in the year and are anticipated to provide important insights into the role of AβOs in Alzheimer’s disease. Supported by our recent financing, we are also advancing toward clinical candidate nomination in our EBD program, with an IND filing targeted for mid-2027. Pairing a commitment to scientific innovation with a track record of strong execution, we believe that we are well-positioned to deliver differentiated treatment options for Alzheimer’s patients.”
Recent Highlights
- In March 2026, the Company announced a
$35.75 million private placement to advance candidates in its AβO-selective EBD portfolio, following strong preclinical data, including in vitro, in vivo and non-human primate study results.- Candidates exceeded key preclinical criteria, demonstrating elevated brain exposure in non-human primates up to 40-fold over native antibodies, low risk of anemia, and robust stability profiles to enable subcutaneous administration.
- Lead clinical candidate Investigational New Drug (IND) filing targeted for mid-2027.
- In March 2026 and in November 2025, the Company presented one oral and four poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) and the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference.
- At AD/PD, the presentations highlighted new data regarding the EBD program, sabirnetug biomarker treatment responses, and the development of new AβO-targeting antibodies.
- At CTAD, results presented from a collaborative study with JCR Pharmaceuticals demonstrated that bispecific antibodies that target transferrin (TfR) as well as the AβO-targeting antibody sabirnetug achieved increased brain penetration in mice while preserving target binding. Results presented on clinical trial recruitment from the Phase 2 ALTITUDE-AD clinical trial showed that site databases and physician referrals were the most reliable recruitment methods overall.
- Presentations are available on the Company’s website here.
- In November 2025, the Company dosed the first patient in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in patients with early Alzheimer's disease.
- The OLE provides all participants who completed the 18-month placebo-controlled double-blind portion of ALTITUDE-AD, including patients previously treated with placebo, with the opportunity to receive sabirnetug at 35 mg/kg administered intravenously once every four weeks for up to 52 weeks.
Anticipated Milestones
- The Company expects topline results from ALTITUDE-AD, a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease, in late 2026.
- The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.
2025 Financial Results
- Cash Balance. As of Dec. 31, 2025, cash, cash equivalents and marketable securities totaled
$116.9 million compared to cash, cash equivalents and marketable securities of$136.1 million as of Sept. 30, 2025. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into early 2027.
- Research and Development (R&D) Expenses. R&D expenses were
$104.9 million for the year ended Dec. 31, 2025, compared to$93.8 million for the year ended Dec. 31, 2024. The increase was primarily due to an increase in manufacturing and materials mainly associated with our ALTITUDE-AD clinical trial, as well as personnel-related costs and research expenses, including EBD research.
- General and Administrative (G&A) Expenses. G&A expenses were
$18.9 million for the year ended Dec. 31, 2025, compared to$20.2 million for the year ended Dec. 31, 2024. The decrease was primarily due to reductions in recruiting expenses, corporate insurance expenses and consulting costs.
- Loss from Operations. Loss from operations was
$123.8 million for the year ended Dec. 31, 2025, compared to$114.0 million for the year ended Dec. 31, 2024. This increase was due to the increased R&D expenses over the prior year period.
- Net Loss. Net loss was
$121.3 million for the year ended Dec. 31, 2025, compared to$102.3 million for the year ended Dec. 31, 2024.
Conference Call Details
Acumen will host a conference call and live audio webcast today, Mar. 26, 2026, at 8:00 a.m. ET.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.
About ALTITUDE-AD (Phase 2)
Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. Topline results are expected in late 2026. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. JCR continues to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. JCR’s innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, the potential for additional development to support a subcutaneous dosing option of sabirnetug, Acumen’s plans to develop a candidate to treat Alzheimer's Disease utilizing EBD technology, including its expectations with respect to timing for the submission of an IND, as well as its potential for developing a best-in-class therapeutic candidate for people living with Alzheimer’s Disease. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.
CONTACTS:
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
ICR Healthcare
AcumenPR@icrhealthcare.com
| Acumen Pharmaceuticals, Inc. | ||||||||
| Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 53,989 | $ | 35,627 | ||||
| Marketable securities, short-term | 62,876 | 135,930 | ||||||
| Prepaid expenses and other current assets | 5,387 | 6,749 | ||||||
| Total current assets | 122,252 | 178,306 | ||||||
| Marketable securities, long-term | - | 59,968 | ||||||
| Restricted cash | 231 | 232 | ||||||
| Other assets, long-term | 350 | 486 | ||||||
| Total assets | $ | 122,833 | $ | 238,992 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 554 | $ | 5,648 | ||||
| Accrued clinical trial expenses | 10,616 | 15,344 | ||||||
| Accrued expenses and other current liabilities | 10,072 | 6,615 | ||||||
| Debt, short-term | 8,765 | - | ||||||
| Total current liabilities | 30,007 | 27,607 | ||||||
| Debt, long-term | 22,396 | 29,419 | ||||||
| Other liabilities, long-term | - | 150 | ||||||
| Total liabilities | 52,403 | 57,176 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, | - | - | ||||||
| Common stock, | 6 | 6 | ||||||
| Additional paid-in capital | 516,803 | 506,985 | ||||||
| Accumulated deficit | (446,462 | ) | (325,127 | ) | ||||
| Accumulated other comprehensive income (loss) | 83 | (48 | ) | |||||
| Total stockholders' equity | 70,430 | 181,816 | ||||||
| Total liabilities and stockholders' equity | $ | 122,833 | $ | 238,992 | ||||
| Acumen Pharmaceuticals, Inc. | ||||||||
| Statements of Operations and Comprehensive Loss | ||||||||
| (in thousands, except share and per share data) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 104,885 | $ | 93,798 | ||||
| General and administrative | 18,947 | 20,219 | ||||||
| Total operating expenses | 123,832 | 114,017 | ||||||
| Loss from operations | (123,832 | ) | (114,017 | ) | ||||
| Other income (expense) | ||||||||
| Interest income | 7,447 | 14,317 | ||||||
| Interest expense | (4,224 | ) | (4,068 | ) | ||||
| Change in fair value of embedded derivatives | (460 | ) | 1,590 | |||||
| Other expense, net | (266 | ) | (151 | ) | ||||
| Total other income | 2,497 | 11,688 | ||||||
| Net loss | (121,335 | ) | (102,329 | ) | ||||
| Other comprehensive gain (loss) | ||||||||
| Unrealized gain (loss) on marketable securities | 131 | (360 | ) | |||||
| Comprehensive loss | $ | (121,204 | ) | $ | (102,689 | ) | ||
| Net loss per common share, basic and diluted | $ | (2.00 | ) | $ | (1.71 | ) | ||
| Weighted-average shares outstanding, basic and diluted | 60,561,836 | 60,013,277 | ||||||
| Acumen Pharmaceuticals, Inc. | ||||||||
| Statements of Cash Flows | ||||||||
| (in thousands) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (121,335 | ) | $ | (102,329 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 58 | 63 | ||||||
| Stock-based compensation expense | 9,852 | 9,635 | ||||||
| Amortization of premiums and accretion of discounts on marketable securities, net | (809 | ) | (5,015 | ) | ||||
| Change in fair value of embedded derivatives | 460 | (1,590 | ) | |||||
| Amortization of right-of-use asset | 126 | 115 | ||||||
| Realized gain on marketable securities | (59 | ) | (97 | ) | ||||
| Noncash interest expense | 1,288 | 1,118 | ||||||
| Other noncash expense | - | 232 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | 1,362 | (3,656 | ) | |||||
| Other long-term assets | 40 | 74 | ||||||
| Accounts payable | (5,094 | ) | 4,269 | |||||
| Accrued clinical trial expenses | (4,728 | ) | 10,957 | |||||
| Accrued expenses and other liabilities | 3,301 | 32 | ||||||
| Finance lease liability | - | (23 | ) | |||||
| Net cash used in operating activities | (115,538 | ) | (86,215 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchases of marketable securities | (38,056 | ) | (170,731 | ) | ||||
| Proceeds from maturities and sales of marketable securities | 172,077 | 218,774 | ||||||
| Purchases of property and equipment | (88 | ) | (16 | ) | ||||
| Net cash provided by investing activities | 133,933 | 48,027 | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of common stock, net of issuance costs | - | 7,938 | ||||||
| Proceeds from exercise of stock options | 39 | - | ||||||
| Payment for financing lease | - | (739 | ) | |||||
| Payments for deferred offering costs | - | (230 | ) | |||||
| Repurchase of common shares to pay employee withholding taxes | (73 | ) | (41 | ) | ||||
| Net cash (used in) provided by financing activities | (34 | ) | 6,928 | |||||
| Net change in cash and cash equivalents and restricted cash | 18,361 | (31,260 | ) | |||||
| Cash and cash equivalents and restricted cash at the beginning of the period | 35,859 | 67,119 | ||||||
| Cash and cash equivalents and restricted cash at the end of the period | $ | 54,220 | $ | 35,859 | ||||
FAQ
When does Acumen (ABOS) expect topline results from the ALTITUDE-AD Phase 2 trial?
How much cash did Acumen (ABOS) report at Dec 31, 2025 and how long is the runway?
What was Acumen's 2025 net loss and how did R&D spending change for ABOS in 2025?
What financing did Acumen (ABOS) complete to support its EBD program in March 2026?
What preclinical EBD data did Acumen (ABOS) report that supports brain delivery?
When is Acumen targeting an IND filing for its lead EBD clinical candidate (ABOS)?
